Medtronic’s Solitaire Gets STRATIS Real-World Stroke Boost

Registry data presented at the International Stroke Conference confirm that mechanical thrombectomy with Medtronic’s Solitaire stent retriever can be safely performed in community hospitals as effectively as it was in the randomized trials observed in randomized trials. The results also show that the benefits of transferring a patient with an acute ischemic stroke to a comprehensive stroke center are usually not worth the extra time it takes to transport the patient there.

CT Scan-Brain_1200x675

Results from the STRATIS registry shows that community hospitals can treat acute stroke patients with mechanical thrombectomy using Medtronic PLC’s Solitaire stent retriever as effectively as comprehensive stroke centers at teaching hospitals. The study found that the benefits of transferring these patients to specialized centers is outweighed by the potential for additional brain damage that can result from the extra time it takes to get there.

STRATIS (Systematic Evaluation Of Patients Treated With Neurothrombectomy Devices For Acute Ischemic Stroke) is a prospective, multicenter single-arm registry designed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurology

UK Center To Develop Brain Stimulation Devices Opens

 

Backed by £50m of UK government funding, the new research center will delve into neural dynamics to develop novel devices ranging from brain implants to wearables.

FDA Regulations ‘Lock Out’ Clinically Proven Neuromodulation Devices

 

Flow Neuroscience's neuromodulation headset for the treatment of depression is approved and marketed in the EU. However, two years on, the company is still waiting for US FDA approval despite being assigned breakthrough device designation.

New Openwater Data Shows Promise For AI-Driven Optical Rapid Stroke Detection

 
• By 

Openwater is currently focusing on EMS applications of its AI-powered stroke detection technology, both in-hospital and prehospital, such as in ambulances and urgent care centers.

Remepy To Embed AI In Next-Gen Digital Therapeutics For Personalized Neuroimmune Modulation

 
• By 

Remepy is exploring two potential regulatory pathways to support this strategy. The first is a combination product pathway that would formally integrate software and drug into a single therapeutic entity. The second is the FDA’s Prescription Drug Use-Related Software (PDURS) pathway.

More from Device Area

Medtronic’s ‘Strategic Expansion’ Into Remote Monitoring

 

“The Corsano wearable strengthens Medtronic’s acute care and monitoring portfolio,” Marc De Martini, vice president at Medtronic, told Medtech Insight.

European Commission Asks For ‘Open Minds’ On Unified Drug/Device Research Pathway

 
• By 

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.

No Strings Attached: Big Players Chase Insulet In Fast-Growing Tubeless Insulin Pump Market

 
• By 

Medtronic, Tandem and Beta Bionics are gearing up to bring tubeless patch pumps to market, chasing Insulet’s Omnipod 5, the only FDA-cleared patch pump for type 1 and type 2 diabetes. Analysts expect tubeless models to eventually displace durable pumps.